McGraw Meghan, White Heath D, Zolfaghari Kiumars, Hochhalter Angela, Arroliga Alejandro, Boethel Carl
Division of Pulmonary, Critical Care and Sleep Medicine, Baylor Scott and White Health, Temple, Texas, United States.
Chronic Obstr Pulm Dis. 2021 Jan;8(1):117-23. doi: 10.15326/jcopdf.2020.0172.
Hospital admissions and readmissions for chronic obstructive pulmonary disease (COPD) exacerbations are associated with increased mortality and higher cost. The management of exacerbations with a shortened course of systemic corticosteroids has similar efficacy as compared to longer steroid courses, but actual overall steroid dose given is still variable. The outcomes associated with steroid side effects, such as hyperglycemia, need further evaluation. We hypothesized that the use of higher doses of corticosteroids, and the subsequent hyperglycemia, contributes to readmission.
This is a retrospective study at a tertiary care referral center in central Texas between February 2014 and July 2016. Daily corticosteroid dose, blood glucose levels, and readmission rates at 30 and 31-90 days were recorded. Sample characteristics are described using descriptive statistics. A chi-square test or student's test were used to test for associations in bivariate comparisons. Multivariable logistic regression assessed the association between readmission rate and demographic and clinical characteristics.
There were 1120 patients admitted for COPD exacerbation between February 2014 and July 2016. A total of 57% were female, mean age was 69 years (standard deviation [SD] 12), and average body mass index (BMI) was 29.4 (SD 9.8). Of the total, 349 (31%) had diabetes prior to admission. The 30-day readmission rate was 16%, and the readmission rate from 31-90 days was 14%. The average prednisone equivalent dose per day during hospitalization was 86 mg (SD 52). A multivariable logistic regression model did not show any significant association between readmission and average daily glucose, high maximum glucose (>180 mg/dL on any reading), or prednisone equivalent administered per day.
Corticosteroid dose and hyperglycemia were not associated with an increased 30-day or 31-90-day readmission rate after COPD exacerbation discharge. In addition, using higher doses of corticosteroids instead of standard-of-care (prednisone 40 mg per day for a 5-day period) did not appear to affect the readmission rate in this cohort.
慢性阻塞性肺疾病(COPD)急性加重导致的住院和再入院与死亡率增加及成本上升相关。与较长疗程的全身用糖皮质激素相比,缩短疗程治疗急性加重具有相似的疗效,但实际给予的糖皮质激素总剂量仍存在差异。与糖皮质激素副作用(如高血糖)相关的结局需要进一步评估。我们假设使用较高剂量的糖皮质激素及随后出现的高血糖会导致再入院。
这是一项在德克萨斯州中部一家三级医疗转诊中心进行的回顾性研究,时间跨度为2014年2月至2016年7月。记录每日糖皮质激素剂量、血糖水平以及30天和31 - 90天的再入院率。使用描述性统计描述样本特征。采用卡方检验或学生检验进行双变量比较中的关联性检验。多变量逻辑回归评估再入院率与人口统计学和临床特征之间的关联。
2014年2月至2016年7月期间,共有1120例因COPD急性加重入院的患者。其中57%为女性,平均年龄69岁(标准差[SD]12),平均体重指数(BMI)为29.4(SD 9.8)。总计349例(31%)患者入院前患有糖尿病。30天再入院率为16%,31 - 90天再入院率为14%。住院期间每日泼尼松等效剂量平均为86毫克(SD 52)。多变量逻辑回归模型未显示再入院与平均每日血糖、最高血糖值高(任何一次读数>180毫克/分升)或每日给予的泼尼松等效剂量之间存在任何显著关联。
COPD急性加重出院后,糖皮质激素剂量和高血糖与30天或31 - 90天再入院率增加无关。此外,在该队列中,使用较高剂量的糖皮质激素而非标准治疗方案(泼尼松每日40毫克,共5天)似乎并未影响再入院率。